Search results
2 kwi 2024 · Universal vaccination: To reduce community transmission and protect individuals with HIV, this committee agrees with the CDC recommendations for universal vaccination against COVID-19 for adults (≥18 years old) with HIV, regardless of prior history of COVID-19 infection.
The ultra-rapid vaccination course (three vaccine doses given over 3 weeks) is immunogenic and can improve completion rates in healthy adults. However, a randomised study comparing the ultra rapid-vaccine course (0, 7, and 21 days) with the typical course (0, 1, and 6 months) in HIV-positive adults found that the former had reduced ...
10 sty 2024 · People with HIV presenting with CD4 count <200 cells/mm 3 with ongoing risk for HAV should be immunized and assessed for antibody response 1 to 2 months after completion of the series. For people with HIV without risk factors, waiting for a CD4 count >200 cells/mm 3 is an option.
The HPTN 084 trial showed that cabotegravir administered intramuscularly every 8 weeks was effective in preventing HIV infection in women at substantial risk for acquiring HIV in sub-Saharan Africa.
21 lis 2021 · The HIV vaccine field has successfully developed multiple vaccine platforms through advanced clinical studies; however, the modest efficacy signal of the RV144 Thai trial remains the only demonstration of HIV vaccine protection in humans.
1 sie 2014 · Current recommendations advise administration of the pneumococcal conjugate vaccine (i.e., Prevnar-13) at the time of HIV diagnosis, followed by PPV23 given ≥8 weeks later.
3 lip 2024 · Risk of Live Vaccines in Persons with HIV. Immunizations are generally safe in individuals with HIV, except for live virus vaccines in persons with low CD4 counts. In those individuals with HIV who have advanced immunosuppression, live vaccines can cause a potentially life-threatening disseminated infection with the live pathogen in the vaccine.
